Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Brii Bio Partners with Sinopharm to Distribute COVID mAb Therapy in China

publication date: Mar 30, 2022

Beijing’s Brii Bio partnered with Sinopharm Holding to distribute Brii’s COVID neutralizing mAb therapy in China. The therapy was developed by combining non-competing SARS-CoV-2 monoclonal neutralizing antibodies derived from convalesced COVID-19 patients. In late 2021, it was approved in China for adults and pediatric patients with mild COVID-19 at high risk for progression to severe disease. Brii is a China-US company that develops therapies for infectious diseases such as hepatitis B virus (HBV), HIV, resistant gram-negative infections, and other conditions including CNS diseases. More details...

Stock Symbol: (HK: 2137)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
September 20-21 | Shanghai
September 25-26 | Digital
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China